{"DataElement":{"publicId":"5733115","version":"1","preferredName":"Diagnostic Imaging Positive Finding Distant Metastasis Site FDG-Positron Emission Tomography Avidity Lesion Indicator","preferredDefinition":"Indicator of whether of not FDG-PET avid lesion was detected at sites of distant metastatic disease.","longName":"FDG_PET_DS_MET_AVD_LSN_DTC_IN","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5733106","version":"1","preferredName":"Diagnostic Imaging Positive Finding Distant Metastasis Site FDG-Positron Emission Tomography Avidity Lesion","preferredDefinition":"Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism._Far apart in space from a point of origin on the body._The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor._A position in relation to its surroundings._An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule (fludeoxyglucose) FDG. FDG is an analogue of glucose which when imaged will give tissue metabolic activity, in terms of regional glucose uptake._Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","longName":"2321520v1.0:5733108v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2321520","version":"1","preferredName":"Diagnostic Imaging","preferredDefinition":"Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation..","longName":"C16502","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnostic Imaging","conceptCode":"C16502","definition":"Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0F852B-00C3-7140-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"PWEST","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5733108","version":"1","preferredName":"Distant Metastasis Site FDG-Positron Emission Tomography Avidity Lesion Positive Finding","preferredDefinition":"Far apart in space from a point of origin on the body.:The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor.:A position in relation to its surroundings.:An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule (fludeoxyglucose) FDG. FDG is an analogue of glucose which when imaged will give tissue metabolic activity, in terms of regional glucose uptake.:Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody.:A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.:A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","longName":"5733108v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Distant","conceptCode":"C25321","definition":"Far apart in space from a point of origin on the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Metastasis","conceptCode":"C19151","definition":"The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Site","conceptCode":"C37901","definition":"A position in relation to its surroundings.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"FDG-Positron Emission Tomography","conceptCode":"C103400","definition":"An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule (fludeoxyglucose) FDG. FDG is an analogue of glucose which when imaged will give tissue metabolic activity, in terms of regional glucose uptake.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Avidity","conceptCode":"C16297","definition":"Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C5E3C55-6400-7B80-E053-F662850AB506","latestVersionIndicator":"Yes","beginDate":"2017-04-04","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-04","modifiedBy":"ONEDATA","dateModified":"2017-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C5E3C55-63B1-7B80-E053-F662850AB506","latestVersionIndicator":"Yes","beginDate":"2017-04-04","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-04","modifiedBy":"MAESKEB","dateModified":"2019-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"FDGPET_DS_MET_AVD_LSN_IND","type":"OID, COG","context":"COG"}],"ReferenceDocuments":[{"name":"Was there an FDG-PET avid les","type":"Preferred Question Text","description":"Was there an FDG-PET avid lesion detected at site(s) of distant metastatic disease?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"If Yes, Was there an FDG-PET avid lesion detected at site(s) of distant metastatic disease?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C5EA40D-DB06-4C0F-E053-F662850A798D","latestVersionIndicator":"Yes","beginDate":"2017-04-04","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-04","modifiedBy":"COBARRUBIAK","dateModified":"2019-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}